Serum fetuin-A, cardiovascular risk factors, and six-year follow-up outcome in patients with coronary heart disease.

High circulating fetuin-A has recently been linked to risk of primary cardiovascular disease (CVD). The clinical importance of fetuin-A in patients at markedly increased cardiovascular risk, however, has not been fully elucidated. We studied the association between serum fetuin-A and future cardiovascular outcome in patients with prevalent coronary heart disease (CHD). Fetuin-A levels were measured in 1,049 patients with CHD. Associations with traditional cardiovascular risk factors and with secondary CVD events during 6 years of follow-up (median 73.4 months, interquartile range 57.4 to 74.3) were analyzed. Serum fetuin-A levels were significantly increased in patients with prevalent hypertriglyceridemia (0.71 vs 0.69 g/L, p = 0.013). No association with baseline metabolic syndrome was found (odds ratio 0.95 for highest vs lowest fetuin-A quintile, 95% confidence interval 0.59 to 1.53, p = 0.82). In Cox proportional hazards analyses, serum fetuin-A levels were not significantly associated with secondary CVD events (hazard ratio 0.67 for highest vs lowest fetuin-A quintile, 95% confidence interval 0.37 to 1.21, p = 0.18). In conclusion, fetuin-A is significantly associated hypertriglyceridemia but not with other traditional cardiovascular risk factors or metabolic syndrome in patients with manifest CHD. Measurement of serum fetuin-A levels may not emerge as a valuable tool for evaluating future CVD risk in patients aggressively treated for advanced atherosclerosis.